脂肪酸从头合成重编程在肺癌耐药中的研究进展  

Research progress of de novo synthesis reprogramming of fatty acids in lung cancer drug resistance

作　　者：赖雅婷 陈采欣 赵钟祥[2] 金晶[1] LAI Yating;CHEN Caixin;ZHAO Zhongxiang;JIN Jing(School of Pharmacy,Sun Yat-sen University,Guangzhou 510006,China;School of Traditional Chinese Medicine,Guangzhou University of Chinese Medicine,Guangzhou 510006,China)

机构地区：[1]中山大学药学院,广东广州510006 [2]广州中医药大学中药学院,广东广州510006

出　　处：《药学研究》2025年第3期265-269,274,共6页Journal of Pharmaceutical Research

基　　金：国家自然科学基金项目(No.82274146)。

摘　　要：肺癌是全世界最致命和最常见的癌症之一。酪氨酸激酶抑制剂(TKIs)可以靶向表皮生长因子受体(EGFR)来治疗肺癌,但患者在治疗后往往会出现耐药性。脂肪酸的从头合成代谢重编程被认为是导致肺癌耐药的重要原因,因此,靶向脂肪酸合成相关酶可能为开发抗肺癌耐药方案提供新的方向。本文综述了肺癌中脂肪酸从头合成与耐药性的关系,并探讨了重要酶和关键蛋白在其中的功能和作用,为开发肺癌耐药治疗新策略和潜在靶向药物提供参考。Lung cancer is one of the most lethal and common cancers in the world.Tyrosine kinase inhibitors(TKIs)can target epidermal growth factor receptor(EGFR)to treat lung cancer,but patients often develop drug resistance after treatment.De novo metabolic reprogramming of fatty acids is considered to be an important reason for drug resistance in lung cancer.Therefore,targeting fatty acid synthesis related enzymes may provide a new direction for the development of anti drug resistance schemes in lung cancer.This article reviewed the relationship between de novo fatty acid synthesis and drug resistance in lung cancer,and discussed the functions and roles of important enzymes and key proteins in it,providing references for the development of new strategies and potential targeted drugs for the treatment of drug resistance in lung cancer.

关 键 词：脂肪酸从头合成 脂质代谢 肺癌 耐药 表皮生长因子受体 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]